Mythreye Karthikeyan, PhDUniversity of South Carolina Specific targeting of Inhibin in ovarian cancers lacking the Type-III TGF-β receptor Ovarian cancer is associated with a high degree of heterogeneity (meaning the tumors differ from patient to patient), highlighting the importance of developing individualized treatment. Changes in the levels of the growth factors belonging to the Transforming […]
Read More
Denise Connolly, PhDFox Chase Cancer Center2015 Pape Family Pilot Award Sensitizing ovarian cancer to PARP inhibition PARP inhibitors are among the most promising class of targeted therapeutics for the treatment of ovarian cancer. Patients with mutations in BRCA genes and some patients with sporadic cancers are particularly sensitive to this class of drugs, presumably because […]
Read More
Andrew Wilson, PhDVanderbilt University Prognostic Significance of TR3/NR4A1 Expression in Ovarian Cancer A key clinical problem in the management of advanced ovarian cancer is tumor resistance to traditional platinum drugs and to newer drugs that inhibit the PARP protein (PARPi). Dr. Wilson will investigate an innovative approach to improve the effects of platinum drugs and […]
Read More
Weei-Chin Lin, MD, PhDBaylor College of Medicine Target a new mechanism of checkpoint defect in ovarian cancer Normal cellular growth is regulated by a process called replication checkpoint. Most ovarian cancers contain the tumor suppressor p53 that is mutated and therefore interferes with proper replication checkpoint function. Dr. Lin’s preliminary data uncovered a novel activity […]
Read More
Ilana Chefetz, PhDUniversity of Minnesota, Twin Cities Deciphering molecular mechanism of ALDH-inhibition driven necroptosis Dr. Chefetz-Menaker recently demonstrated that chemotherapy resistant ovarian cancer stem-like cells (CSC) can be identified by a protein activity known as ALDH. The expression of ALDH in CSC allows a unique opportunity to develop therapeutics specifically targeting CSC, which are thought […]
Read More
Fiona Yull, D.Phil.Vanderbilt University Bromodomain inhibition in ovarian cancer and the tumor microenvironment Scientists are actively working to find new therapies for ovarian cancer as resistance to current therapies, including PARP inhibitors and cisplatin, poses a major problem in the clinic. One promising approach is to develop strategies that activate the patient’s normal immune system […]
Read More
Yunfei Wen, PhDUniversity of Texas MD Anderson Cancer Center Overcoming acquired resistance to antiangiogenic therapy by targeting vascular p130cas Angiogenesis, the process of forming a new network of blood vessels from existing ones, is a central hallmark of cancer. In order for a tumor to grow, it must have the blood flow necessary to feed […]
Read More
Carlos Telleria, PhDMcGill University Health Center Proteotoxic Stress Therapy in Ovarian Cancer The majority of ovarian cancers recur 18-24 months after first responding to chemotherapy. Residual cells hide out in the abdominal cavity and often become unresponsive to current chemotherapy when they grow back. Dr. Telleria researches therapies that would be administered chronically after chemotherapy […]
Read More
Fiona Simpkins, MDUniversity of Pennsylvania School of Medicine Circumventing drug resistance mechanisms in CCNE1 amplified ovarian cancers More than 80% of patients with high-grade serous ovarian cancer (HGSOC) develop resistance to treatment and eventually succumb to their disease. The need to develop new treatments for this form of ovarian cancer is dire. About 65% of […]
Read More
Richard Moore, MDUniversity of Rochester Targeting HE4 for Checkpoint Immunotherapy of Ovarian Cancer HE4 is a protein that is highly overproduced in ovarian cancer cells and secreted into the bloodstream and serves as a biomarker for the presence of ovarian cancer. However, HE4 is also causally linked to tumorigenesis by promoting enhanced growth, blood vessel […]
Read MoreStarting April 1, 2025, the Rivkin Center’s ovarian cancer research funding, global symposium and fundraising activities will continue under the leadership of Ovarian Cancer Research Alliance (OCRA).
